Sources
Newsquawk
🇺🇸US pre-market movers🇺🇸 ES +0.1% NQ +0.1% RTY -0.1% $LLY +0.9%: Verzenio medication showed improvement; upgraded at HSBC to 'Hold' from 'Underperform' $UNH -0.4%: DoJ has expanded its criminal probe into $UNH $SJM -3.2%: Q1 Adj. EPS, Q1 rev. and FY26 adj. EPS outlook all
Palmer $LLY According to FactSet, the average price target on the Indianapolis-based drug company is $913. After the HSBC upgrade, there are no firms with the equivalent of a sell rating on Eli Lilly, according to FactSet. HSBC upgrades Eli Lilly to Hold with bear case played out -
TipRanks HSBC upgrades Eli Lilly $LLY to Hold, while Truist Financial and Citi maintain Buy ratings. Shares closed at $736.03. Positive insider sentiment with recent purchases.
